The medtech giant shared its findings at New York Valves 2026: The Structural Heart Summit, in multiple presentations.
Abbott’s TriClip transcatheter edge-to-edge repair (TEER) offers an option for those who aren’t good candidates for surgery and continue to have symptoms or persistent tricuspid regurgitation (TR) despite treatment with medical therapy. Delivered through a vein in the leg, the TriClip TEER technology clips together a portion of leaflets. It repairs the tricuspid valve and helps blood flow in the right direction without the need for open-heart surgery.
Navitor is a transcatheter aortic valve implantation (TAVI) system. Abbott designed Navitor as the only self-expanding TAVI system with leaflets within the native valve. This design helps improve access to coronary arteries to facilitate future procedures that treat coronary artery disease.
Amulet 360, a next-generation left atrial appendage occlusion (LAAO) implant, was designed to reduce the risk of stroke in patients with AFib not caused by a heart valve issue (non-valvular).
A look at the findings shared by Abbott
TriClip
The TriClip presentation shared new data from the company’s TVT registry of 3,035 patients across 278 U.S. sites who underwent TriClip procedures. Abbott says it further demonstrates the device’s safety and effectiveness as a therapy for tricuspid regurgitation (TR).
Key 30-day findings included significant TR reduction to moderate or les in 87% of patients. Patients had more than a 22-point improvement on average in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score. Investigators also saw low rates of adverse events. That includes major bleeding (0.9%) and new permanent pacemaker (0.5%).
Navitor
The second presentation evaluated real-world outcomes from the TVT registry of using Abbott’s Navitor valve to treat patients with small aortic annuli. This patient population (primarily female) historically faces higher risks of patient-prosthesis mismatch.
Key 30-day takeaways included 98.2% of patients with mild or less paravalvular leak (PVL). Investigators reported a 7.5mm Hg mean gradient, indicating a low average pressure difference. This allows blood to pump out smoothly with minimal strain on the heart.
Despite challenging small anatomies, just 5.3% of patients experienced severe prosthesis-patient mismatch (PPM). Abbott said this directly addresses a historical vulnerability for this patient population.
Amulet 360
Abbott also shared new results from its VERITAS study for the investigational Amulet 360 LAA Occluder.
The new analysis on the 45-day data evaluated the safety, effectiveness and procedural efficiency in 53 implanters participating in the study across the U.S., Canada and Europe. Investigators grouped procedures among physicians’ experience levels. That included roll-ins (first procedure), early (between one to five procedures within analysis cohort), and experienced (more than five procedures).
Results came from 458 total procedures across 34 sites.
Key findings included 100% implant success after the implanter’s fifth case. Investigators also saw complete closure (omm peri-device leak) in the majority of cases, from roll-ins (84.3%) to experienced (96.1%). Procedural efficiency improved with implanter experience as well.
Abbott said the findings build on the previously reported 0% primary safety event rate at seven days. Amulet 360 remains investigational globally.
